Palisade Bio (PALI) Total Non-Current Liabilities (2012 - 2026)
Palisade Bio (PALI) reported Total Non-Current Liabilities of $5.9 million for Q1 2026, up 106.2% year-over-year from $2.9 million in Q1 2025, and up 20.18% quarter-over-quarter from $4.9 million in Q4 2025.
Palisade Bio (PALI) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Palisade Bio (PALI) has 15 years of Total Non-Current Liabilities data on file, last reported at $5.9 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $5.9 million, up 106.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (up 106.2% YoY), and the FY2025 annual result was $4.9 million, up 44.69% from the prior year.
- Total Non-Current Liabilities grew to $5.9 million in Q1 2026 per PALI's latest filing, from $4.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $5.9 million in Q1 2026 and troughed at $1.5 million in Q1 2023.
- A 5-year average of $3.2 million and a median of $2.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities decreased 20.41% in 2023, then soared 106.2% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $3.3 million in 2022, then dropped by 18.45% to $2.7 million in 2023, then rose by 26.51% to $3.4 million in 2024, then jumped by 44.69% to $4.9 million in 2025, then climbed by 20.18% to $5.9 million in 2026.
- Business Quant data shows PALI's Total Non-Current Liabilities at $5.9 million in Q1 2026, $4.9 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 64.76 Mn |
| 10 | Palisade Bio | 357.48 Mn | 227.91 Mn | - | 5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.89 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 2.77 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 3.44 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.92 Mn |
| Jun 30, 2021 | 3.87 Mn |